 SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 GLOBE NEWSWIRE -- Tenaya Therapeutics, Inc. NASDAQ: TNYA, a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that it will present new preclinical data on its novel AAV capsids for cardiac gene delivery at the 29th Annual Congress of the European Society of Gene and Cell Therapy ESGCT, October 11 - 14, 2022 in Edinburgh, Scotland. 